Hepatic cytoreduction followed by a novel long-acting somatostatin analog: A paradigm for intractable neuroendocrine tumors metastatic to the liver
- 1 December 2001
- Vol. 130 (6) , 954-962
- https://doi.org/10.1067/msy.2001.118388
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Role for Surgical Cytoreduction in Multimodality Treatments for CancerAnnals of Surgical Oncology, 2001
- Hepatic neuroendocrine metastases: does intervention alter outcomes?1Journal of the American College of Surgeons, 2000
- Treatment of liver metastases in patients with neuroendocrine tumors.Langenbecks Archives Of Surgery, 1998
- How I Do It: Intraoperative use of radiofrequency treatment allows an increase in the rate of curative liver resectionJournal of Surgical Oncology, 1998
- Cryosurgical palliation of metastatic neuroendocrine tumors resistant to conventional therapySurgery, 1997
- Laparoscopic thermal ablation of hepatic neuroendocrine tumor metastasesSurgery, 1997
- Metastatic Endocrine Tumors: Medical Treatment, Surgical Resection, or Liver TransplantationWorld Journal of Surgery, 1996
- Hepatic resection for metastatic neuroendocrine carcinomasThe American Journal of Surgery, 1995
- Streptozocin–Doxorubicin, Streptozocin–Fluorouracil, or Chlorozotocin in the Treatment of Advanced Islet-Cell CarcinomaNew England Journal of Medicine, 1992
- Karnofsky memorial lecture. An odyssey in the land of small tumors.Journal of Clinical Oncology, 1987